SGLT2-remmers, ook bij kwetsbare ouderen?

Translated title of the contribution: SGLT2 inhibitors, also in frail older adults?

Dorianne M. van Bruggen, David R. M. Jansen, Eveline P. van Poelgeest

Research output: Contribution to journalReview articleProfessional

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) have gained prominence in the treatment of diabetes mellitus type 2, heart failure, and chronic kidney disease. However, concerns arise for frail older adults, given their underrepresentation in trials and heightened susceptibility to adverse drug events. This review summarizes the clinical effects of SGLT2 inhibitors in older adults with frailty. SGLT2 inhibitors seem to exhibit consistent cardiovascular benefits irrespective of age. As such, these drugs can be beneficial for older adults with 'cardiovascular frailty': in other words, cardiovascular multimorbidity. However, in the current data there is a lack of focus on the broader definition of frailty, which also includes functional status and self-dependence. Also, some research suggest that adverse events, such as volume depletion and genitourinary infections, are more common in the frail older population. Therefore, until more data is available, SGLT2 inhibitors should be prescribed with caution in older adults living with frailty.
Translated title of the contributionSGLT2 inhibitors, also in frail older adults?
Original languageDutch
JournalNederlands Tijdschrift voor Geneeskunde
Volume168
Publication statusPublished - 11 Apr 2024

Cite this